NASDAQ:AADI Aadi Bioscience (AADI) Stock Price, News & Analysis $1.40 +0.07 (+4.89%) (As of 10:33 AM ET) Add Compare Share Share Today's Range$1.34▼$1.4050-Day Range$1.32▼$2.1252-Week Range$1.28▼$7.24Volume25,419 shsAverage Volume315,697 shsMarket Capitalization$34.25 millionP/E RatioN/ADividend YieldN/APrice Target$20.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Aadi Bioscience alerts: Email Address Aadi Bioscience MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,369.5% Upside$20.50 Price TargetShort InterestBearish5.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 4 Articles This WeekInsider TradingSelling Shares$122,655 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.54) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.68 out of 5 starsMedical Sector618th out of 879 stocksPharmaceutical Preparations Industry289th out of 417 stocks 3.3 Analyst's Opinion Consensus RatingAadi Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAadi Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Aadi Bioscience's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.24% of the float of Aadi Bioscience has been sold short.Short Interest Ratio / Days to CoverAadi Bioscience has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Aadi Bioscience has recently increased by 2.74%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAadi Bioscience does not currently pay a dividend.Dividend GrowthAadi Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AADI. Previous Next 1.7 News and Social Media Coverage News SentimentAadi Bioscience has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aadi Bioscience this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aadi Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $122,655.00 in company stock.Percentage Held by Insiders37.30% of the stock of Aadi Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.08% of the stock of Aadi Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aadi Bioscience's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aadi Bioscience are expected to decrease in the coming year, from ($2.54) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aadi Bioscience is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aadi Bioscience is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAadi Bioscience has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aadi Bioscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About Aadi Bioscience Stock (NASDAQ:AADI)Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Read More AADI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AADI Stock News HeadlinesJuly 3, 2024 | insidertrades.comNeil Desai Sells 31,348 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) StockJuly 5 at 1:07 PM | investorplace.com3 Russell 2000 Stocks to Sell in July Before They Crash & BurnJuly 8, 2024 | Oasis Gold (Ad)New Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.July 3, 2024 | americanbankingnews.comAadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai Sells 31,348 Shares of StockMay 29, 2024 | prnewswire.comAadi Bioscience to Participate in the Jefferies Healthcare ConferenceMay 23, 2024 | prnewswire.comAadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 15, 2024 | marketwatch.comArcutis Biotherapeutics Shares Climb 24% on 1Q Revenue SurgeMay 11, 2024 | finance.yahoo.comAadi Bioscience, Inc. (NASDAQ:AADI) Analysts Are Cutting Their Estimates: Here's What You Need To KnowJuly 8, 2024 | Oasis Gold (Ad)New Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.May 10, 2024 | finance.yahoo.comAnalysts Just Made A Major Revision To Their Aadi Bioscience, Inc. (NASDAQ:AADI) Revenue ForecastsMay 9, 2024 | washingtonpost.comArlo Technologies: Q1 Earnings SnapshotMay 9, 2024 | insidermonkey.comAadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comAadi Bioscience First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comAadi Bioscience Inc (AADI) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...May 8, 2024 | investorplace.comAADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comAadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate UpdateMay 7, 2024 | markets.businessinsider.comAadi Bioscience is about to announce its earnings — here's what to expectMay 1, 2024 | prnewswire.comAadi Bioscience to Report First Quarter 2024 Results and Corporate UpdateSee More Headlines Receive AADI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/08/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AADI CUSIPN/A CIK1422142 Webaadibio.com Phone(424) 473-8055FaxN/AEmployees75Year FoundedN/APrice Target and Rating Average Stock Price Target$20.50 High Stock Price Target$36.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,369.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,760,000.00 Net Margins-288.72% Pretax Margin-288.72% Return on Equity-61.83% Return on Assets-51.52% Debt Debt-to-Equity RatioN/A Current Ratio5.16 Quick Ratio4.86 Sales & Book Value Annual Sales$24.35 million Price / Sales1.41 Cash FlowN/A Price / Cash FlowN/A Book Value$4.29 per share Price / Book0.33Miscellaneous Outstanding Shares24,550,000Free Float15,395,000Market Cap$34.25 million OptionableOptionable Beta0.69 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Neil P. Desai Ph.D. (Age 59)Founder & Executive Chairman Comp: $710.35kMr. David J. Lennon Ph.D. (Age 53)President, CEO & Director Comp: $277.75kMr. Scott M. Giacobello CPA (Age 54)CFO, Treasurer, Investor Relations & Corporate Communications Comp: $643.23kDr. Loretta M. Itri F.A.C.P. (Age 74)M.D., Chief Medical Officer Comp: $617.45kMr. Stephen M. Rodin J.D. (Age 48)Senior VP of Legal & General Counsel Mr. Raymond G. Steitz (Age 65)Senior VP of Human Resources & Chief Human Resources Officer Mr. Bryan Ball (Age 54)Chief Quality Officer & Senior VP of Manufacturing Operations More ExecutivesKey CompetitorsAllakosNASDAQ:ALLKAkoya BiosciencesNASDAQ:AKYAI-MabNASDAQ:IMABTelomir PharmaceuticalsNASDAQ:TELOGalectin TherapeuticsNASDAQ:GALTView All CompetitorsInsiders & InstitutionsNeil DesaiSold 31,348 sharesTotal: $45,454.60 ($1.45/share)Marquette Asset Management LLCBought 57,807 shares on 5/7/2024Ownership: 0.235%Neil DesaiSold 40,000 sharesTotal: $77,200.00 ($1.93/share)Neil DesaiSold 17,772 sharesTotal: $41,053.32 ($2.31/share)Neil DesaiSold 14,964 sharesTotal: $31,424.40 ($2.10/share)View All Insider TransactionsView All Institutional Transactions AADI Stock Analysis - Frequently Asked Questions How have AADI shares performed this year? Aadi Bioscience's stock was trading at $2.02 on January 1st, 2024. Since then, AADI stock has decreased by 30.9% and is now trading at $1.3950. View the best growth stocks for 2024 here. How were Aadi Bioscience's earnings last quarter? Aadi Bioscience, Inc. (NASDAQ:AADI) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by $0.02. The firm had revenue of $5.35 million for the quarter, compared to the consensus estimate of $6.41 million. Aadi Bioscience had a negative net margin of 288.72% and a negative trailing twelve-month return on equity of 61.83%. When did Aadi Bioscience's stock split? Aadi Bioscience shares reverse split on the morning of Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Aadi Bioscience? Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AADI) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aadi Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aadi Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
